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Background and Purpose–We assessed the efficacy and safety of antiplatelet agents after 43 
noncardioembolic stroke or TIA and examined how these vary according to patients’ 44 
demographic and clinical characteristics. 45 
Methods –We did a network meta-analysis (NMA) of data from six randomized trials of the 46 
effects of commonly prescribed antiplatelet agents in the long-term (≥ 3 months) secondary 47 
prevention of non-cardioembolic stroke or TIA. Individual patient data from 43,112 patients 48 
were pooled and reanalyzed. Main outcomes were: serious vascular events (non-fatal stroke, 49 
non-fatal myocardial infarction or vascular death), major bleeding and net clinical benefit 50 
(serious vascular event or major bleeding). Subgroup analyses were done according to age, 51 
sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large vs. small 52 
vessel disease), and time from qualifying event to randomization. 53 
Results–Aspirin/dipyridamole combination (RRNMA-adj 0.83, 95%CI 0.74-0.94) significantly 54 
reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj 0.88, 55 
95%CI 0.78-0.98) and aspirin/clopidogrel combination (RRNMA-adj 0.83, 95%CI 0.71-0.96). 56 
Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than 57 
aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. 58 
Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, 59 
aspirin/dipyridamole combination and clopidogrel. Net clinical benefit was similar for 60 
clopidogrel and aspirin/dipyridamole combination (RRNMA-adj 0.99, 95%CI 0.93-1.05). 61 
Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified 62 
subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination 63 
compared with clopidogrel alone was higher in patients aged <65 years than it was in 64 
patients ≥65 years (RRNMA-adj 3.9 vs. 1.7). 65 
Conclusions–Results favor clopidogrel and aspirin/dipyridamole combination for long-term 66 
secondary prevention after non-cardioembolic stroke or TIA, regardless of patient 67 
characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk 68 






















    
    
    
    
    
    
    
    









Stroke survivors are at increased risk of recurrent ischemic events, including recurrent stroke 72 
and myocardial infarction.1 Particularly in the first hours and days after a TIA or stroke, risk of 73 
recurrence is high.2;3 Recurrent strokes lead to dementia more often and have higher case 74 
fatality than first strokes.4 Antiplatelet therapy is a cornerstone in secondary prevention and 75 
successfully reduces the frequency of vascular events5; for patients with noncardioembolic 76 
stroke or TIA the relative risk reduction of aspirin was 13%.6 77 
Guidelines vary, but most recommend aspirin, aspirin/dipyridamole combination or 78 
clopidogrel as first-line treatment in long-term secondary prevention after noncardioembolic 79 
stroke or TIA.7;8 Given the mixed evidence and important differences between various 80 
antiplatelet agents, it becomes challenging for clinicians to select an optimal agent for an 81 
individual patient. 82 
A few network meta-analyses (NMA) have been performed to compare the long-term efficacy 83 
of antiplatelet therapies among patients with stroke or TIA9-13; however, these analyses were 84 
performed on aggregated data from randomized controlled trials that included patients with 85 
different underlying causes of ischemic stroke/TIA. As a result, these analyses could not 86 
adequately restrict their study population to patients with noncardioembolic stroke or TIA, 87 
while appropriate use of antiplatel t drugs after TIA or ischemic stroke depends on whether 88 
the underlying cause is cardioembolic or not. Furthermore, these analyses based on 89 
published, aggregate data could not deal with differences in reported outcome definitions 90 
(for example vascular death including or excluding hemorrhagic deaths from any origin). 91 
Also, not all trials reported the results of intracranial hemorrhage or major bleeding, thus 92 
some comparisons between antiplatelet therapies for safety outcomes were lacking. In 93 
addition, individual trials are usually not powered for subgroup analyses and meta-analyses 94 
using published aggregate data on subgroups have substantial limitations because of the 95 
inability to systematically adjust for potential confounders. A pooled individual participant 96 
data (IPD) analytic approach is most suitable for assessing subgroup effects with sufficient 97 
power and adequate adjustment for potential confounders.14 98 
Therefore, we performed an individual patient data network meta-analysis to compare the 99 
efficacy and safety of antiplatelet therapies frequently used for long-term secondary stroke 100 






















    
    
    
    
    
    
    
    









Study population 104 
A detailed description of the design of the individual patient data network meta-analysis 105 
(IPD-NMA) has been described elsewhere.15 Briefly, we obtained data for patients from trials 106 
investigating the efficacy of antiplatelet therapy in long-term secondary prevention after a 107 
TIA or ischemic stroke. Trials were eligible if they randomised patients with TIA or ischemic 108 
stroke to antiplatelet regimens (monotherapy or dual therapy) for long-term secondary 109 
prevention after stroke. Because homogeneity and consistency assumptions underlie  110 
network meta-analysis,16 we did not include RCTs assessing aspirin versus placebo because 111 
such studies had a wide range of daily doses (75-1500 mg). Although the benefit of aspirin is 112 
quite consistent at low, medium and high doses of aspirin6, side effects appear to be dose 113 
related. Another reason for excluding these RCTs is that the evaluation of antiplatelet therapy 114 
versus placebo has become less clinically important. We also excluded randomized studies of 115 
short-duration (<3 months), those that only assessed surrogate outcomes, or those that 116 
specifically focused on patients with lacunar infarcts. Studies that examined triflusal, 117 
cilostazol, terutroban, ticlopidine, or dipyridamole alone were also excluded, as our interest 118 
was to evaluate the efficacy and safety of commonly prescribed antiplatelet regimens in 119 
patients with noncardioembolic ischemic stroke or TIA. We used the methods described in 120 
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 121 
Requests for access to data from the Cerebrovascular Antiplatelet Trialists’ (CAT) database 122 
will be considered by the CAT Steering Committee. 123 
 124 
Data extraction 125 
For all eligible trials, we sought to obtain individual patient data. Data were obtained on the 126 
following baseline variables: demographics (age, sex, ethnicity), smoking, medical history 127 
(hypertension, hypercholesterolemia, diabetes mellitus, history of stroke or TIA, history of 128 
cardiovascular disease, history of heart failure), clinical presentation (nature of qualifying 129 
event [TIA vs. minor ischemic stroke], type of vessel involved [small vessel disease vs. large 130 
vessel disease] time from event to randomization, severity of stroke at entry) and randomized 131 
treatment allocation (aspirin, clopidogrel, aspirin/dipyridamole combination, 132 






















    
    
    
    
    
    
    
    







following outcome variables: any recurrent stroke, recurrent ischemic stroke, myocardial 134 
infarction, major bleeding, intracranial bleeding, and cause of any deaths. All data were 135 
merged into a single composite database, the CAT database. Detailed consideration was 136 
given to the definitions of baseline variables used in the original trials. When definitions were 137 
identical, comparable data were merged. If possible, differences in definitions of baseline 138 
variables between studies were resolved by reconstruction of definitions to achieve 139 
comparability. We excluded patients with a possible cardioembolic origin of their TIA or 140 
stroke (those with a history of atrial fibrillation or TOAST classification cardio-embolic stroke).  141 
 142 
Redefinition of outcome events  143 
Detailed consideration was given to the outcome definitions used in the original trial reports. 144 
We accepted the reported definitions of ischemic stroke, intracranial hemorrhage (including 145 
intracerebral hemorrhage, subarachnoid hemorrhage, and epidural and subdural 146 
hematomas), all-cause mortality, death from non-vascular causes and myocardial infarction 147 
as defined by the trial investigators and did not attempt to retrospectively reclassify events.15 148 
Composite outcome definitions of stroke and vascular death vary across the trials.15 For the 149 
combined analysis, subdural and epidural hematomas were counted as intracranial 150 
hemorrhages, but not as strokes.15 Vascular death includes hemorrhagic deaths from any 151 
origin.15 152 
 153 
The primary efficacy outcomes of interest were: serious vascular events (defined as the 154 
composite of stroke, myocardial infarction [MI] or vascular death) and ischemic events 155 
(composite of ischemic stroke, MI, or vascular death [excluding hemorrhagic death]. Primary 156 
safety outcomes were major (including fatal) bleeding and primary intracranial hemorrhage. 157 
There were minor differences in definition of major bleeding between trials15, but 158 
designations made in the original trials were not changed. Major bleedings were fatal, 159 
intracranial, required hospital admission or led to significant disability. Secondary exploratory 160 
outcomes included net clinical benefit outcome (defined as the composite of stroke, 161 






















    
    
    
    
    
    
    
    







Statistical analysis 163 
All analyses were by intention to treat based on the randomized treatment allocation. For 164 
each outcome, we cross-checked individual data against previous publications (see Table I in 165 
the online-only Data Supplement). Second, we calculated unadjusted and adjusted risk ratios 166 
for each outcome within each trial with Poisson regression with robust standard errors. In the 167 
adjusted analyses we account for the following prespecified covariates: age, sex, 168 
hypertension, diabetes, current smoking, qualifying diagnosis (stroke vs. TIA). Pooled 169 
unadjusted and adjusted risk ratios were obtained by random-effects network meta-analyses 170 
with package netmeta in R. We estimated ranking probabilities for all antiplatelet regimens of 171 
being at each possible rank for each treatment. The treatment hierarchy was summarized and 172 
reported as Surface Under the Cumulative RAnking curve (SUCRA), which measure the 173 
average probability that a treatment is better than the competing treatments.17 The network 174 
results were assessed for consistency by comparing them with the results from individual 175 
trials or pairwise meta-analyses (Table I in the online-only Data Supplement). To investigate 176 
the consistency of the primary results, we also did an analysis of patients who used treatment 177 
(on-treatment analysis), in which we included only the outcome events that arose while study 178 
treatment was being taken or before the 28th day after the discontinuation of treatment.  179 
Third, to determine whether the results were affected by patient characteristics, we did 180 
subgroup network meta-analyses for the main outcomes (serious vascular events and major 181 
bleeding) according to the following characteristics: sex, age (<65 vs. ≥65 years), ethnicity 182 
(Asian vs. non-Asian), hypertension (yes vs. no), qualifying diagnosis (stroke vs. TIA), type of 183 
vessel involved (large vs. small vessel disease), and time from qualifying event to 184 
randomization (≤21 days vs. >21 days). These variables were selected following a review of 185 
risk scores, clinical guidelines, trial subgroup analyses and clinical advice.7;8;18-23 All subgroup 186 
analyses are reported as adjusted effects (adjusted for the same prespecified covariates as in 187 
the primary analyses). Fourth, we performed several sensitivity analyses in which we either 188 
omitted the MATCH trial where only patients with ischemic stroke/TIA at high vascular risk 189 
were included, or omitted the CHARISMA trial where patients with previous symptomatic 190 
cerebrovascular disease within the previous five years were included, or omitted the ESPRIT 191 
trial in which an open, non-blinded study design was used. We did analyses with IBM SPSS 192 






















    
    
    
    
    
    
    
    









Six trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT and PRoFESS19-24) met the inclusion 196 
criteria, including 48,023 patients with a TIA or ischemic stroke recruited between 1989 and 197 
2006. Table II in the online-only Data Supplement presents the main characteristics of the six 198 
trials. After exclusion of patients randomized to placebo or dipyridamole alone (n=3,303) and 199 
patients with a possible cardioembolic origin of their stroke (n= 1,608), 43,112 patients 200 
remained for the analyses. The antiplatelet treatment comparisons are visualized in a network 201 
(Figure 1). Detailed results of the individual trials and pairwise meta-analyses are given in 202 
Table I in the online-only Data Supplement. 203 
Patient characteristics stratified by trial arm are presented in Table 1. The median time to 204 
randomization was 21 days (range 15 to 124) and patients were followed for a median of 2.0 205 
years (1.5 to 3.5). Mean age was 65 years (SD 10) and 36% were female. Ninety percent had a 206 
stroke as qualifying event and small vessel disease was diagnosed in 50% of the patients. 207 
Patient characteristics were similar between treatment options, except for a greater 208 
proportion of patients with vascular risk factors in patients treated with clopidogrel 209 
monotherapy or the aspirin/clopidogrel combination, and a greater proportion of patients 210 
with large vessel disease in patients treated with aspirin monotherapy. In terms of study 211 
quality, all six trials were rated as low risk of bias studies (Figure I in the online-only Data 212 
Supplement). 213 
 214 
Serious vascular ev nts 215 
A total of 5,424 (12.6%) serious vascular events and 5,022 (11.6%) ischemic events occurred. 216 
The adjusted network meta-analysis treatment effects are reported in Table 2. The results are 217 
consistent with the unadjusted network meta-analysis results (Table III in the online-only 218 
Data Supplement), the results from individual trials or pairwise meta-analyses (Table I in the 219 
online-only Data Supplement) and the on-treatment analyses. Aspirin/dipyridamole 220 
combination significantly reduced the risk of serious vascular events compared with aspirin 221 
(RRNMA-adj 0.83, 95%CI 0.74 to 0.94), as did clopidogrel (RRNMA-adj 0.88, 95%CI 0.78 to 0.98) and 222 
aspirin/clopidogrel combination (RRNMA-adj 0.83, 95%CI 0.71 to 0.96). There were no 223 
statistically significant differences with respect to the occurrence of serious vascular event 224 






















    
    
    
    
    
    
    
    







aspirin/clopidogrel combination. Similarly, clopidogrel, aspirin/dipyridamole combination and 226 
aspirin/clopidogrel combination significantly reduced the risk of ischemic events compared 227 
with aspirin (RRs range 0.83 to 0.91); aspirin/dipyridamole combination and 228 
aspirin/clopidogrel combination significantly reduced the risk of ischemic stroke compared 229 
with aspirin. 230 
 231 
Major bleeding events 232 
In terms of safety, 1,530 (3.5%) major bleedings and 380 (0.9%) intracranial hemorrhages 233 
occurred. Clopidogrel caused significantly less major bleeding (RRNMA-adj 0.76, 95%CI 0.63 234 
to0.91) and intracranial hemorrhage (RRNMA-adj 0.63, 95%CI 0.43 to 0.91) than aspirin. 235 
Aspirin/dipyridamole combination caused significantly more major bleeding (RRNMA-adj 1.14, 236 
95%CI 1.00 to 1.30) and intracranial hemorrhage (RRNMA-adj 1.40, 95%CI 1.08 to 1.82) than 237 
clopidogrel. Aspirin/clopidogrel combination caused significantly more major bleeding than 238 
aspirin, clopidogrel, and aspirin/dipyridamole combination (Table 2).  239 
The net clinical benefit outcome (serious vascular events or major bleeding) was similar for 240 
clopidogrel and aspirin/dipyridamole combinati n (RRNMA-adj 0.99, 95%CI 0.93 to 1.05). Risk of 241 
this combined outcome was reduced by clopidogrel (RRNMA-adj 0.89, 95%CI 0.82 to 0.96) and 242 
aspirin/dipyridamole (RRNMA-adj 0.87, 95%CI 0.80 to 0.95) compared with aspirin. 243 
 244 
Sensitivity analysis and ranking 245 
All results were similar aft r exclusion of 7,252 (17%) patients with TIA/ischemic stroke at high 246 
vascular risk in MATCH, after exclusion of 4,240 (10%) patients in CHARISMA who had 247 
symptomatic cerebrovascular disease within the previous five years, or after exclusion of 248 
2,739 (6%) patients randomized in ESPRIT in which an open, non-blinded study design was 249 
used (Table IV in the online-only Data Supplement). The ranking of treatments based on 250 
cumulative probability (SUCRA) is presented in Table V in the online-only Data Supplement. 251 
In terms of efficacy, the most effective treatments were aspirin/clopidogrel combination and 252 
aspirin/ dipyridamole combination. Both treatments have a probability around 75% of being 253 
superior to a competing treatment. Clopidogrel has the highest probability of being the best 254 
treatment modality in terms of safety (99%), followed by aspirin/dipyridamole combination 255 
(65%). Combining the rankings for efficacy and safety indicates that both clopidogrel and 256 






















    
    
    
    
    
    
    
    







balance between efficacy and safety (Figure 2 and Table V in the online-only Data 258 
Supplement). 259 
  260 
Subgroup analyses 261 
We also investigated whether the treatment effect differed between certain subgroups of 262 
patients (Table VI in the online-only Data Supplement). For serious vascular events, there was 263 
no evidence of heterogeneity of treatment effect across any of the prespecified subgroups. 264 
Excess risks of major bleeding were similar for most of the subgroups, apart from patient age. 265 
Aspirin/clopidogrel combination showed more major bleeding complications than 266 
clopidogrel, especially in younger patients. The adjusted excess risk for major bleeding varied 267 
from 1.7 times higher (RRNMA-adj 1.7, 95%CI 1.3 to 2.2) in patients aged ≥65 years to an 268 
approximately fourfold excess risk (RRNMA-adj 3.9, 95%CI 2.5 to 6.0) in patients aged <65 years.  269 
This subgroup effect was already apparent in the MATCH trial: patients older than 65 years 270 
assigned to aspirin/clopidogrel had a 1.6 times increased risk of major bleeding (92 [3.0%/y] 271 
of 2,169 patients vs. 54 [1.8%/y] of 2,097 assigned to clopidogrel; RRadj 1.6, 95% CI 1.2–2.3). 272 
Patients younger than 65 years assigned to aspirin/clopidogrel had a fourfold increased risk 273 
of major bleeding (67 [3.2%/y] of 1,466 patients vs. 16 [0.7%/y] of 1,520 assigned to 274 






















    
    
    
    
    
    
    
    









Our collaborative individual patient data network meta-analysis indicates that clopidogrel 278 
and aspirin/dipyridamole combination both showed a favorable balance between efficacy 279 
and safety. Benefits were seen across a wide range of subgroups.  280 
 281 
Long-term combination of clopidogrel and aspirin resulted in significantly more major 282 
bleeding complications compared with aspirin or clopidogrel alone, doubling the number of 283 
events. Also, older age was positively associated with higher bleeding risks for all antiplatelet 284 
regimens. However, major bleeding risk did not further increase in older patients on the 285 
aspirin/clopidogrel combination compared with younger patients, indicating a risk ceiling 286 
effect of about 3% per year. This effect is likely to be related to the fact that patients with 287 
high bleeding risks were not included in the trials, due to strict exclusion criteria or that their 288 
bleeding led to premature death. The unexpected effect of age on treatment effect observed 289 
by pooling these trials was present in the MATCH trial, but has not been reported. Our 290 
findings suggest that future trials of new antiplatelet regimens in long-term stroke 291 
prevention should examine risk of bleeding for younger and older patients separately. Also, 292 
co-prescription of a proton-pump inhibitor could be considered in future studies, as has been 293 
suggested recently.25  294 
 295 
To date, several network meta-analyses have been conducted to assess the effects of 296 
different antiplatelet regimens in the secondary stroke prevention.9-13 One network meta-297 
analysis showed that the aspirin/dipyridamole combination was better than using clopidogrel 298 
or aspirin alone in the secondary prevention of serious vascular events after TIA or ischemic 299 
stroke10; this finding was not consistent with our analysis. We consider the main reason to be 300 
that results of the PRoFESS trial, which showed similar rates of recurrent stroke in patients 301 
receiving aspirin/dipyridamole combination and in patients receiving clopidogrel, were 302 
published after this review. In another network meta-analysis, Malloy et al reported that more 303 
bleeding events seemed to occur with the combination of aspirin and clopidogrel than with 304 
other treatments, and our results are in line with that finding.11 Two recent network analyses 305 
have shown that cilostazol had the best risk-benefit profile for long-term secondary 306 






















    
    
    
    
    
    
    
    







that investigated the effect of cilostazol in the long-term secondary stroke prevention were 308 
performed in patients of Asian descent26-28; therefore the effect of cilostazol may not be 309 
generalizable to non-Asian populations. More randomized controlled trials in non-Asian 310 
patients are needed to determine whether the use of cilostazol is a good option for long-311 
term secondary stroke prevention. Other conventional pairwise meta-analyses focused on the 312 
effect of short-term and long-term dual-antiplatelet therapy compared with 313 
monotherapy.29;30 However, antiplatelet agents used in dual- and single-antiplatelet therapies 314 
varied across trials. 315 
 316 
Analysis of individual patient data has advantages over meta-analysis of overall trial results. 317 
The availability of individual data for a large number of patients enabled us to make a more 318 
precise assessment of the relative treatment effects of antiplatelet agents than has been 319 
possible previously. One of the strengths of our study is the standardized definition of 320 
composite outcomes. Differences between the trials in the definition of composite outcomes 321 
made it previously impossible to combine reported aggregate results satisfactorily. Also, we 322 
could study safety outcomes such as major bleeding and intracranial hemorrhage in more 323 
detail and could restrict our study population to patients with noncardioembolic ischemic 324 
stroke or TIA. Furthermore, we were able to assess potential heterogeneous treatment effects 325 
among different subgroups. We did a network meta-analysis to combine the evidence from 326 
all relevant (direct and indirect) treatment comparisons into one single analysis, while fully 327 
preserving randomization. Although network meta-analysis has been criticized, results from 328 
conventional random-effects meta-analyses of direct within-trial comparisons were 329 
concordant with results from our network meta-analysis.  330 
 331 
Our meta-analysis had some limitations. Although the sample size was large, the ability to 332 
provide adjusted treatment effect estimates for all subgroups analyzed was limited by the 333 
number of patients in each subgroup. Second, too few studies were available to be able to 334 
study between-trial heterogeneity. Third, we compared treatments for several relevant clinical 335 
outcomes and subgroups. Given the strong, predefined rationale (see published protocol15), 336 
we did not explicitly adjust for multiple comparisons. Fourth, trial populations were similar in 337 
many respects, but they varied in some entry criteria. These differences, however, allowed us 338 






















    
    
    
    
    
    
    
    







and additional patient characteristics. The consistency of results across all six trials suggests 340 
that our findings are generalizable to a broad range of patients with noncardioembolic 341 
ischemic stroke or TIA. Fifth, most patients in the secondary stroke prevention trials were 342 
already beyond the very early high risk period after their initial TIA or stroke when recruited. 343 
We found no evidence for differences in treatment effects in patients randomized in the 344 
subacute and late phases, but acute effects might differ. The results of the POINT and 345 
CHANCE trial suggest that the aspirin/clopidogrel combination is beneficial over aspirin alone 346 
when initiated early after stroke and continued for about three weeks.31;32 347 
 348 
Our findings raise questions about the mechanisms by which clopidogrel and 349 
aspirin/dipyridamole combination cause major bleeding. CYP2C19 genetic variants decrease 350 
the efficacy of clopidogrel, but no association between bleeding risk and carrier status is 351 
observed yet.31;33;34 It is therefore not clear if CYP2C19 genetic variants influence the risk of 352 
bleeding. 353 
 354 
Hence, both clopidogrel and aspirin/dipyridamole combination can be used in the long-term 355 
secondary prevention of non-cardioembolic stroke or TIA. The aspirin/clopidogrel 356 
combination significantly increases the risk of major bleeding compared with other 357 
antiplatelet regimens. Given the similar net clinical benefit outcome of clopidogrel and 358 
aspirin/dipyridamole combination, selection of antiplatelet therapy for the secondary 359 
prevention of stroke must be individualized according to patient needs, bleeding risks and 360 
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Figure 1.  Network of randomized controlled trial evidence 
Figure legend: Ellipses represent comparators. Arrows represent comparisons of interventions 
for which trial data were available. Patient numbers represent the total number of patients 
enrolled in each trial informing the comparison of interest. 
  
Figure 2. Clustered ranking plot for the outcomes serious vascular events and major 
bleeding  
Figure legend: The probabilities of each treatment being ranked best in terms of efficacy 
(serious vascular events) and safety (major bleeding) outcomes are represented by their 
Surface Under the Cumulative RAnking curve (SUCRA) values. Treatments lying in the upper 
right corner are more effective in preventing serious vascular events, with lower propensity to 






















    
    
    
    
    
    
    
    







Table 1.  Baseline characteristics of patients included in the trials 
 
ASA  CLO  ASADIP  ASACLO 
 









Age (mean±SD) 65 11  66 9  66 9  66 10 
Female sex 3,011 37%  5,968 36%  4,591 36%  2,139 37% 
Asian ethnicity 420 5%  3,415 21%  3,454 27%  306 5% 
            
Qualifying event characteristics            
Ischemic stroke type 6,756 83%  15,737 95%  11,851 93%  4,471 78% 
Moderately severe disability (mRS 3-5)* 1,113 22%  3,720 24%  2,724 23%  752 26% 
Lacunar stroke subtype** 2,567 43%  7,940 51%  6,559 52%  1,557 54% 
Median time from qualifying event             








  < 7 days 697 9%  2,797 17%  2,477 20%  944 16% 
  7 days to 1 month (30 days) 2,777 34%  7,853 48%  5,642 44%  2,193 38% 
  ≥ 1 month 4,645 57%  5,835 35%  4,571 36%  2,617 45% 
            
Risk factors and medical history            
Current smoking 2,025 25%  3,459 21%  3,018 24%  1,073 19% 
Hypertension 5,097 63%  12,051 73%  8,790 69%  4,447 77% 
Hypercholesterolemia 3,354 41%  7,857 48%  5,530 44%  3,301 57% 
Diabetes mellitus 1,901 23%  6,036 37%  3,325 26%  3,111 54% 
Heart failure 266 4%  623 4%  309 3%  328 6% 
Myocardial infarction 742 9%  1,167 7%  861 7%  316 5% 
Previous stroke† 1,020 13%  3,248 20%  1,972 16%  1,158 20% 
Previous TIA† 977 15%  2,027 12%  1,026 9%  993 17% 
* for patients randomized after an ischemic stroke only, data not collected in CHARISMA; **data not 





























Table 2. Adjusted treatment effect estimates from network meta-analysis for efficacy and safety 
 Serious vascular event Ischemic event Ischemic stroke Major bleeding 
Intracranial 
hemorrhage 
Net clinical benefit 
outcome* 
 RRadj (95%CI) RRadj (95%CI) RRadj (95%CI) RRadj (95%CI) RRadj (95%CI) RRadj (95%CI) 
Compared with Aspirin             
  Clopidogrel 0.88 (0.78-0.98) 0.91 (0.83-0.99) 0.91 (0.81-1.02) 0.76 (0.63-0.91) 0.63 (0.43-0.91) 0.89 (0.82-0.96) 
  Aspirin+dipyridamole 0.83 (0.74-0.94) 0.86 (0.78-0.95) 0.86 (0.76-0.97) 0.86 (0.71-1.05) 0.88 (0.60-1.31) 0.87 (0.80-0.95) 
  Aspirin+clopidogrel 0.83 (0.71-0.96) 0.83 (0.73-0.94) 0.83 (0.71-0.97) 1.63 (1.29-2.07) 1.19 (0.68-2.08) 0.94 (0.84-1.05) 
Compared with clopidogrel 
  
          
  Aspirin+dipyridamole 0.95 (0.85-1.06) 0.95 (0.89-1.02) 0.95 (0.87-1.04) 1.14 (1.00-1.30) 1.40 (1.08-1.82) 0.99 (0.93-1.05) 
  Aspirin+clopidogrel 0.94 (0.82-1.08) 0.91 (0.82-1.02) 0.91 (0.80-1.04) 2.16 (1.72-2.71) 1.88 (1.12-3.16) 1.06 (0.96-1.17) 
Compared with Aspirin+dipyridamole 
  
          
  Aspirin+clopidogrel 0.99 (0.84-1.17) 0.96 (0.85-1.09) 0.96 (0.82-1.13) 1.89 (1.47-2.42) 1.34 (0.77-2.36) 1.08 (0.96-1.20) 
* The net clinical benefit outcome was the composite of stroke, myocardial infarction, vascular death, or major bleeding. adj, adjusted for: age, sex, 
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